30 October 2013
Phase 2 Study Initiated With APD403 In CINV
30 October 2013
Phase 2 Study Initiated With APD403 In CINV15 October 2013
Acacia Pharma Announces Positive Phase 2 Results With APD515 For Xerostomia In Advanced Cancer17 September 2013
Pivotal Phase 3 Studies Initiated With APD421 in PONV03 September 2013
Acacia Pharma Raises £15m ($23.5m) To Advance Clinical Development Of Lead Products01 October 2012
Acacia Pharma Announces Positive Results From Phase 2a Nausea & Vomiting Study In Cancer Patients31 March 2011
Acacia Pharma Closes $10 Million Investment Round07 February 2011
Phase 1 Clinical Trial Completed With APD515 For Xerostomia06 January 2011
New Website Launched06 September 2010
Acacia Pharma to Progress Two Projects for Nausea & Vomiting and Xerostomia into Development14 December 2009
Acacia Pharma Completes Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)08 June 2009
Acacia Pharma Initiates Phase II Study with APD405 in Post-Operative Nausea & Vomiting (PONV)05 February 2009
Ian Kent Appointed as Chairman04 March 2008
Chief Medical Officer Appointed04 March 2008
Gilde Healthcare Investment in Acacia Pharma